These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 1471866

  • 1. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis.
    McFarland HF, Frank JA, Albert PS, Smith ME, Martin R, Harris JO, Patronas N, Maloni H, McFarlin DE.
    Ann Neurol; 1992 Dec; 32(6):758-66. PubMed ID: 1471866
    [Abstract] [Full Text] [Related]

  • 2. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions.
    Smith ME, Stone LA, Albert PS, Frank JA, Martin R, Armstrong M, Maloni H, McFarlin DE, McFarland HF.
    Ann Neurol; 1993 May; 33(5):480-9. PubMed ID: 8498825
    [Abstract] [Full Text] [Related]

  • 3. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history.
    Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF.
    Ann Neurol; 1991 May; 29(5):548-55. PubMed ID: 1859184
    [Abstract] [Full Text] [Related]

  • 4. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
    Paolillo A, Piattella MC, Pantano P, Di Legge S, Caramia F, Russo P, Lenzi GL, Pozzilli C.
    J Neurol; 2004 Apr; 251(4):432-9. PubMed ID: 15083288
    [Abstract] [Full Text] [Related]

  • 5. Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?
    Bonzano L, Roccatagliata L, Mancardi GL, Sormani MP.
    Mult Scler; 2009 Sep; 15(9):1043-7. PubMed ID: 19570818
    [Abstract] [Full Text] [Related]

  • 6. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
    Then Bergh F, Kümpfel T, Schumann E, Held U, Schwan M, Blazevic M, Wismüller A, Holsboer F, Yassouridis A, Uhr M, Weber F, Daumer M, Trenkwalder C, Auer DP.
    BMC Neurol; 2006 May 23; 6():19. PubMed ID: 16719908
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.
    Massacesi L, Parigi A, Barilaro A, Repice AM, Pellicanò G, Konze A, Siracusa G, Taiuti R, Amaducci L.
    Arch Neurol; 2005 Dec 23; 62(12):1843-7. PubMed ID: 16344342
    [Abstract] [Full Text] [Related]

  • 8. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.
    Molyneux PD, Filippi M, Barkhof F, Gasperini C, Yousry TA, Truyen L, Lai HM, Rocca MA, Moseley IF, Miller DH.
    Ann Neurol; 1998 Mar 23; 43(3):332-9. PubMed ID: 9506550
    [Abstract] [Full Text] [Related]

  • 9. Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials.
    Moraal B, van den Elskamp IJ, Knol DL, Uitdehaag BM, Geurts JJ, Vrenken H, Pouwels PJ, van Schijndel RA, Meier DS, Guttmann CR, Barkhof F.
    Ann Neurol; 2010 May 23; 67(5):667-75. PubMed ID: 20437564
    [Abstract] [Full Text] [Related]

  • 10. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC.
    Neurology; 2009 Feb 24; 72(8):705-11. PubMed ID: 19073945
    [Abstract] [Full Text] [Related]

  • 11. [Magnetic resonance imaging in multiple sclerosis].
    Tourbah A, Berry I.
    Pathol Biol (Paris); 2000 Mar 24; 48(2):151-61. PubMed ID: 10815291
    [Abstract] [Full Text] [Related]

  • 12. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis.
    Stone LA, Frank JA, Albert PS, Bash C, Smith ME, Maloni H, McFarland HF.
    Ann Neurol; 1995 May 24; 37(5):611-9. PubMed ID: 7755356
    [Abstract] [Full Text] [Related]

  • 13. Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis.
    Tortorella C, Bellacosa A, Paolicelli D, Fuiani A, Di Monte E, Simone IL, Giaquinto P, Livrea P, Trojano M.
    J Neurol Sci; 2005 Dec 15; 239(1):95-9. PubMed ID: 16209877
    [Abstract] [Full Text] [Related]

  • 14. Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance.
    Barkhof F, van Walderveen M.
    Philos Trans R Soc Lond B Biol Sci; 1999 Oct 29; 354(1390):1675-86. PubMed ID: 10603619
    [Abstract] [Full Text] [Related]

  • 15. Contrast enhancement and the acute lesion in multiple sclerosis.
    Rovaris M, Filippi M.
    Neuroimaging Clin N Am; 2000 Nov 29; 10(4):705-16 ,viii-ix. PubMed ID: 11359720
    [Abstract] [Full Text] [Related]

  • 16. Short-term brain atrophy changes in relapsing-remitting multiple sclerosis.
    Zivadinov R, Bagnato F, Nasuelli D, Bastianello S, Bratina A, Locatelli L, Watts K, Finamore L, Grop A, Dwyer M, Catalan M, Clemenzi A, Millefiorini E, Bakshi R, Zorzon M.
    J Neurol Sci; 2004 Aug 30; 223(2):185-93. PubMed ID: 15337621
    [Abstract] [Full Text] [Related]

  • 17. A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis.
    Rovira A, Swanton J, Tintoré M, Huerga E, Barkhof F, Filippi M, Frederiksen JL, Langkilde A, Miszkiel K, Polman C, Rovaris M, Sastre-Garriga J, Miller D, Montalban X.
    Arch Neurol; 2009 May 30; 66(5):587-92. PubMed ID: 19433658
    [Abstract] [Full Text] [Related]

  • 18. Defining interferon beta response status in multiple sclerosis patients.
    Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E.
    Ann Neurol; 2004 Oct 30; 56(4):548-55. PubMed ID: 15389896
    [Abstract] [Full Text] [Related]

  • 19. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.
    Miller DH, Albert PS, Barkhof F, Francis G, Frank JA, Hodgkinson S, Lublin FD, Paty DW, Reingold SC, Simon J.
    Ann Neurol; 1996 Jan 30; 39(1):6-16. PubMed ID: 8572668
    [Abstract] [Full Text] [Related]

  • 20. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 30; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.